Evercore ISI analyst Umer Raffat believes the odds of a Revlimid patent settlement between Celgene (CELG) and Dr. Reddy's (RDY) have gone up "considerably" following a recent court filing. The filing, according to the analyst, shows Dr. Reddy's agreed to resolve claims construction issues, which he believes "implies a clear alignment in thought process between both sides." A potential settlement on Revlimid remains the biggest catalyst on Celgene in 2018, and could lead a quick re-rating in the valuation multiple, Raffat tells investors in a research note. He keeps Celgene as his top pick for 2018 with an Outperform rating and $155 price target.